• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

Insulet issues warning on certain Omnipod 5 pumps due to manufacturing issue

March 12, 2026 By Sean Whooley

Insulet Omnipod 5 worn on the back of an arm
The Omnipod 5 hybrid closed-loop insulin delivery system worn on the back of an arm. [Image courtesy of Insulet]
Insulet (Nasdaq:PODD) today initiated a voluntary medical device correction for specific lots of Omnipod 5 insulin pump pods.

Omnipod 5 — the world’s first available tubeless, wearable, automated insulin delivery system — is a patch-based pump system designed to proactively correct for glucose highs every five minutes and protect against lows with insulin dosing.

Acton, Massachusetts-based Insulet said it identified a manufacturing issue with certain Omnipod 5 lots through its ongoing product monitoring. Its correction applies to specific identified lots distributed in the U.S. All other Omnipod 5 pods and Omnipod products remain safe to use.

Insulet said that certain pods from specific lots may have a small tear in the internal tubing that delivers insulin. If this occurs, insulin may leak inside the pod rather than infuse into the body as intended. When the pod fails to deliver insulin properly, users may experience high blood glucose levels due to under-delivery.

In severe cases, prolonged and persistent high blood glucose levels can lead to diabetic ketoacidosis (DKA).

According to a news release, Insulet received 18 reports of serious adverse events associated with high blood glucose levels. Those events included hospitalization and DKA. The company reports no deaths related to the issue. It noted that the issue does not affect the continuous glucose monitor (CGM) systems that integrate with Omnipod 5.

Actions taken by Insulet after identifying this issue

Following its investigation, Insulet said it implemented updates to its manufacturing processes and quality controls. These updates aim to strengthen detection and prevention and further support the integrity of its products.

Pods involved in the correction represent approximately 1.5% of annual Omnipod 5 pod production globally.

Insulet continues to manufacture and ship the unaffected systems and does not anticipate disruptions to customer shipments, product availability or new patient starts. The company notified the FDA of its action as well.

“Patient safety and product quality remain Insulet’s highest priorities,” the company said.

Insulet said that customers should visit omnipod.com/check-pods to confirm whether the correction includes their pod lot number. They can request replacement pods at no cost. If users identify that a pod from an affected lot is in current use, customers should discontinue use and replace it with a pod from an unaffected lot.

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Recalls, Technology Tagged With: Insulet

IN CASE YOU MISSED IT

  • MiniMed wins CE mark for next-gen insulin pump, ups revenue guidance
  • Abbott wins FDA authorization for dual glucose-ketone sensor
  • FDA clears Roche’s Alzheimer’s blood test for rule-in and rule-out assessment 
  • MiniMed Flex now integrated with Abbot’s Instinct sensor 
  • Senseonics sees activist investor take a major stake

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS